VGVincent Ganu

Vincent Ganu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vincent Ganu has a total of 98 co-authors. Here are the top co-authors by number of shared publications:

  • Ernest Kenu

    Ghana Field Epidemiology and Laboratory Training Programme, Department of Epidemiology and Disease Control, School of Public Health, University of Ghana, Accra, Ghana

    8 shared publications
  • Margaret Lartey

    Department of Medicine, Korle Bu Teaching Hospital, Accra, Ghana

    7 shared publications
  • Peter Puplampu

    5 shared publications
  • Kofi Agyabeng

    Department of Biostatistics, School of Global Public Health, New York University, New York, New York, United States of America

    4 shared publications
  • Kwasi Torpey

    Department of Population, Family, Reproductive Health, School of Public Health, University of Ghana, Accra, Ghana

    4 shared publications
  • Peter Puplampu

    Department of Medicine and Therapeutics University of Ghana Medical School, Accra, Ghana

    4 shared publications

Latest Publications

  • Open Access

    Healthcare providers’ perspectives on multilevel barriers to antiretroviral therapy adherence among adolescents and young adults living with HIV in Ghana: a qualitative study

    byĀ Vincent Ganu, Louiza Twumasi, Anna Gyaban-Mensah, Priscilla Etornam Selly, Maame Ama Ackah, Anita Ago Asare, Olive Asafu-Adjaye, Dzifa Dey, Ernest Yorke, Vincent Boima, et al.

  • Open Access

    Willingness to accept long-acting injectable antiretroviral therapy among persons living with HIV in a tertiary facility in Southern Ghana: Key consideration for programming

    byĀ Peter Puplampu, Vincent Ganu, Isaac Kyeremateng, Emmanuella Ayinbisa Amankwa, Oluwakemi Oladele, Francisca Zigah, Kofi Agyabeng

    There a gradual transformation of the HIV epidemic with the emergence of antiretroviral therapy. Adherence to daily pill intake is vital for optimal HIV viral suppression. A strategic approach to enhancing adherence is the development of long-acting injectable ART (LAI-ART). Patients’ willingness to accept LAI-ART is a key determinant to the success of these novel therapies, but data is lacking in Africa and Ghana. This study assessed the willingness to accept LAI-ART among patients attending HIV clinic in Accra, Ghana. A cross-sectional study was conducted among 309 patients attending HIV clinic at the Infectious Disease Center of the Korle-Bu Teaching Hospital from July to October 2023. Data on perspectives on LAI-ART was collected using a structured questionnaire. Willingness was measured after exposure to a structured educational session to increase awareness or knowledge on LAI-ART. Descriptive statistics was used to summarize the demographic and clinical characteristics. Bivariate and multivariate analysis was performed with Fisher’s exact or Chi square test and logistic regression respectively. Most (71.5%) participants were female, above 50 years (46.3%) and were employed (70.6%). Majority were on a single-pill regimen (80.2%), adherent (86.7%), and had no prior awareness about LAI-ART (69.9%). After structured educational session, 89.6% showed a preference for LAI-ART, with a preferred frequency of injections every 6 months (67.3%). Almost 50% did not prefer self-administration of LAI- ART. Thirty-two percent had concerns about LAI-ART, and about 72% of PLHIV were willing to pay for LAI-ART. Participants’ willingness to accept LAI-ART reflected a hypothetical or informed preference and potential acceptability rather than observed behavior due to structured educational session. More education on LAI-ART is needed. LAI- ART presents an opportunity to increase access and adherence to HIV treatment. Further studies assessing potential barriers and how to address them will aid in the success of this treatment regimen.

  • Open Access

    Elevated Serum Lipopolysaccharides and Intrinsic Factor Autoantibodies Correlate With Macrocytic Anemia Among People With HIV

    byĀ Daniel Amakye, Samuel Hammond, Osbourne Quaye, Upal Roy, Peter Puplampu, Vincent Ganu, Emmanuel Ayitey Tagoe

    Introduction: Human immunodeficiency virus (HIV) infection is associated with various comorbidities, including macrocytic anemia, though the role of the infection is unclear. HIV has been implicated in microbial translocation and altered immune responses. This study aimed to establish the relationship between gut microbial translocation and immune response, and macrocytic anemia among people with HIV (PWH). Materials and Methods: Fifty‐five PWH on combination antiretroviral therapy (cART) were age‐matched with 55 HIV‐negative individuals. Demographic data and blood samples were collected from February to July 2023. Hematological indices, including red blood cell (RBC) count, hemoglobin concentration, and mean corpuscular volume (MCV), were measured. Serum lipopolysaccharides (LPS) and intrinsic factor autoantibodies (IFAA) were measured using ELISA. Results: The prevalence of macrocytic anemia was significantly higher in the HIV cohort (43.6%) compared to HIV‐negative individuals (1.8%), ( p < 0.0001). PWH exhibited higher microbial translocation, characterized by elevated LPS levels ( p < 0.0001). PWH with macrocytic anemia showed significantly increased serum LPS and IFAA levels compared to those without anemia ( p < 0.001). Intrinsic factor autoantibodies correlated positively with systolic ( r = 0.49, p < 0.001) and diastolic blood pressures ( r = 0.31, p < 0.01), as well as LPS ( r = 0.60, p < 0.001) and MCV ( r = 0.65, p < 0.001). Conclusion: This study reports for the first time elevated lipopolysaccharides and intrinsic factor autoantibodies among PWH, and the lipopolysaccharides and intrinsic factor autoantibodies strongly correlated with mean corpuscular volume in the patients. Targeting serum lipopolysaccharides and intrinsic factor autoantibodies may offer a novel therapeutic strategy.

  • Open Access

    Metabolic syndrome among a Ghanaian cohort living with HIV initiated on dolutegravir in a real-world setting: a prospective study

    byĀ Kwasi Torpey, Vincent Ganu, Ernest Kenu, Stephen Ayisi Addo, Kofi Agyabeng, Magdalene Akos Odikro, Raphael Adu-Gyamfi, Abdul Gafaru Mohammed, Margaret Lartey

    Objectives The use of antiretroviral therapy has been linked to the development of some components of metabolic syndrome (MetS), specifically glucose intolerance, weight gain and defective lipid metabolism. This study determined the relationship between dolutegravir (DTG) and MetS in a cohort of persons living with HIV (PWH) initiating DTG-based regimen in Ghana. Design A 2-year observational prospective study was conducted from September 2020 to August 2022. Setting Five HIV high-burden facilities providing antiretroviral therapy services at the district and tertiary levels of care in Ghana. Participants Persons with HIV who were newly enrolled onto DTG. Primary and secondary outcome measures Waist circumference, body mass index, blood pressure, fasting blood glucose and lipids were the primary outcomes measured at baseline, 3, 6, 12 and at 18 months follow-up to determine the incidence of MetS. MetS was defined using the Joint Consensus definition that combines the International Diabetes Federation and the National Cholesterol Education Programme Adult Treatment Panel III (ATP III) definitions. The Kaplan-Meier estimator was used to estimate the risk of developing MetS. The Cox proportional hazard model was used in estimating HRs. Results Of 3664 PWH screened at baseline, 31.4% (1152/3664) had MetS. Of the remaining 2512 with no MetS at baseline, there were 960 incident cases of MetS over the 1.5 years follow-up. The estimated MetS incident rate is 384.2 (95% CI: 360.6 to 409.2) per 1000 person-years with a median time to development of MetS at 6 months (IQR; 3–12 months). Being female (adjsuted HR, aHR: 1.42, 95% CI: 1.19 to 1.70), age ≄50 years (aHR: 1.30, 95% CI: 1.12 to 1.51), having a comorbidity at baseline (aHR: 1.39, 95% CI: 1.12 to 1.51) and being overweight (aHR: 1.46, 95% CI: 1.25 to 1.71) and obese (aHR: 1.62, 95% CI: 1.36 to 1.93) were associated with higher risk of MetS development. Conclusions The incidence of MetS was high among our patients, with elevated fasting blood sugar and elevated blood pressure being the most common developed MetS defining components. HIV programmes should institute targeted interventions at addressing central obesity to reduce the risk of MetS.


  • Open Access

    Depressive Symptoms Among Adolescents and Young Adults Living With HIV on Antiretroviral Therapy: Outcomes From a Cross‐Sectional Study in Accra, Ghana

    byĀ Vincent Ganu, Kwasi Torpey, Margaret Lartey, Delali Fiagbe, Magdalene Akos Odikro, Veronika Shabanova, Elijah Paintsil, Ernest Kenu

    Introduction: Systematic screening for depression among adolescents and young adults living with HIV (AYALHIV) is limited or nonexistent in some settings in sub‐Saharan Africa due to the lack of integration of mental healthcare into HIV program. This can increase the risk of suicidal thoughts and cause emotional distress, which can have an adverse effect on their treatment outcomes. Establishing evidence of the burden of depression among AYALHIV is key for advocacy for systematic screening. This study examined the burden of depressive symptoms and associated factors among AYALHIV in Ghana. Methods: A single‐center facility‐based cross‐sectional study was conducted among AYALHIV at the Infectious Disease Center of the Korle Bu Teaching Hospital, Accra, Ghana, from May 2023 to March 2024. Depressive symptoms were assessed through the administration of the Patient Health Questionnaire for Adolescents (PHQ‐A). The prevalence of depressive symptoms (PHQ‐A score ≄ 5) and associated factors was examined using logistic regression. Results: A total of 280 AYALHIV were recruited with 50.7% being female. Sixty percent were young adults, and the rest were adolescents. About 75% were virally suppressed. The prevalence of depressive symptoms was 40.7% (95% CI: 34.9%–46.7%). Being an orphan (adjusted odds ratio [aOR] = 2.6, 95% confidence interval [95% CI]: 1.2–5.6), female (aOR = 1.8, 95% CI 1.1–3.0), and having high perceived stigma (aOR = 2.2, 95% CI: 1.3–3.7) were associated with having depressive symptoms. Viral nonsuppression was associated with depressive symptoms but likely through its association with HIV stigma. Conclusion: Depressive symptom burden was high among AYALHIV despite viral suppression in the majority of them. There is a need for the design of mental health screening integration into youth‐centered HIV programs based on context for early identification, counseling, and treatment of mental health challenges to ensure good quality of life and avert other mental health challenges.


  • Open Access

    Incidence of type 2 diabetes mellitus in persons living with HIV initiated on dolutegravir-based antiretroviral regimen in Ghana: an observational longitudinal study

    byĀ Margaret Lartey, Ernest Kenu, Vincent Ganu, Stephen Ayisi Addo, Kofi Agyabeng, Delia Bandoh, Marijanatu Abdulai, Prince Tsekpetse, Kwasi Torpey

    Few studies have reported hyperglycemia and diabetic ketoacidosis in patients on dolutegravir (DTG) treatment. This study determined the effect of DTG on fasting blood glucose levels in a cohort of persons living with HIV (PLHIV) in Ghana and initiating DTG regimens. A two-year observational longitudinal cohort study conducted from 12th October 2020 to 31st December 2022. Fasting blood glucose was measured at baseline, 12, 24, 36 and 72 weeks for patients after a 12 h overnight fast. The Kaplan-Meier estimator was used to estimate the risk of developing type 2 diabetes mellitus (T2DM). Cox proportional hazard model was used in estimating hazard ratios. A total of 1334 non-diabetic patients were enrolled with 78% (1039) females and 83% (1104) were antiretroviral therapy experienced. The incidence proportion and rate of T2DM at 72 weeks were 11.8% (95%CI: 10.2–13.7) and 98.1 cases per 1000 PY (95%CI: 83.9-114.6) respectively. The median time to development of T2DM was 24 weeks post DTG initiation. Male sex (aHR 2.9 [95%CI: 1.9–4.3]), abnormal waist-hip ratio (1.67 [95% CI: 1.15–2.43]) and abnormal total serum cholesterol (aHR 1.6 [95%CI: 1.1–2.3]) were found to be significant determinants of T2DM. Incidence of T2DM is high among non-diabetic PLHIV within 72 weeks of initiating DTG based therapy with males having a higher risk. Longitudinal changes in waist-hip ratio and serum cholesterol among patients initiated on DTG needs to be monitored regularly.


  • Open Access

    Opportunistic Infections among newly diagnosed HIV patients in the largest tertiary facility in Ghana

    byĀ Peter Puplampu, Olive Asafu-Adjaye, Marian Harrison, John Tetteh, Vincent Jessey Ganu

    Annals of Global Health is a peer-reviewed, fully open access, online journal dedicated to publishing high quality articles dedicated to all aspects of global health. The journal's mission is to advance global health, promote research, and foster the prevention and treatment of disease worldwide. Its goals are to improve the health and well-being of all people, advance health equity, and promote wise stewardship of the earth's environment. The latest journal impact factor is 2.90. Annals of Global Health is supported by the Program for Global Public Health and the Common Good at Boston College. It was founded in 1934 by the Icahn School of Medicine at Mount Sinai as the Mount Sinai Journal of Medicine. It is a partner journal of the Consortium of Universities for Global Health. From time to time, Annals of Global Health publishes Special Collections, a series of articles organized around a common theme in global health. Recent Special Collections have included "Local evidence and strategies in addressing NCDs Non-Communicable Diseases in Tanzania", "Universal Health Coverage through Integrated Care", and "The Minderoo-Monaco Commission on Plastics and Human Health". Global health workers interested in developing a Special Collection are strongly encouraged to contact the Managing Editor in advance to discuss the project.


  • Open Access

    Hypertension Among Cohort of Persons With Human Immunodeficiency Virus Initiated on a Dolutegravir-Based Antiretroviral Regimen in Ghana

    byĀ Margaret Lartey, Kwasi Torpey, Vincent Ganu, Stephen Ayisi Addo, Delia Bandoh, Marijanatu Abdulai, Golda Akuffo, Ernest Kenu

    Background: Dolutegravir (DTG), a new antiretroviral drug, is being integrated into antiretroviral regimens for people with human immunodeficiency virus (PWH) in Ghana. There is little evidence of the effect of DTG on blood pressure (BP) levels in sub-Saharan Africa, especially West Africa. Our aim was to assess the incidence and predictors of hypertension (HTN) among PWH initiated on a DTG-based antiretroviral regimen in Ghana. Methods: An observational multicenter longitudinal study was conducted among PWH in Ghana from 2020 to 2022. BPs of nonhypertensive patients with BP ≤120/80 mm Hg at baseline were measured at 3, 6, 12, and 18 months post–DTG initiation. The primary outcome of the study was incidence of HTN, defined as BP ≄140/90 mm Hg. Kaplan-Meier estimator was used to estimate risk of developing HTN. Cox proportional hazards model with robust standard errors was used to estimate hazard ratios (HRs). Results: HTN prevalence among PWH screened was 37.3% (1366/3664). The incidence of de novo HTN among nonhypertensive PWH at 72 weeks was 598.4 per 1000 person-years (PY) (95% confidence interval [CI], 559.2–640.3) with incidence proportion of 59.90 (95% CI, 57.30–62.44). A quarter of those with de novo HTN developed it by month 6. Obesity (adjusted HR [aHR], 1.27 [95% CI, 1.05–1.54]), abnormal serum urea (aHR, 1.53 [95% CI, 1.27–1.85]), and low high-density lipoprotein (aHR, 1.45 [95% CI, 1.22–1.72]) were risk factors for HTN. Conclusions: Incidence of HTN was high among PWH on DTG. There is a need to monitor BP for HTN in adult PWH as well as traditional risk factors to reduce the burden of HTN and its complications.


  • Open Access

    Clinico-epidemiological characteristics of adolescents and young adults living with HIV in Ghana

    byĀ Vincent Ganu, Oluwakemi Oladele, Emmanuella Amankwa, Rafiq Okine, Peter Puplampu

    INTRODUCTION: Sub-Saharan Africa is experiencing a boom in the number of adolescents and young adults living with HIV (AYALHIV). Existing HIV intervention programs are mainly for children and adults living with HIV, with little attention paid to AYALHIV. Characterizing this population is necessary for planning, and designing, AYALHIV-centered HIV intervention programs. METHODS: a retrospective single-center, hospital-based chart review was conducted at the largest HIV clinic in Ghana. We examined routinely collected data for AYALHIV (aged 10-24 years) on antiretroviral therapy (ART) for at least 1 year and in active care from 1stJanuary to 31st December 2019. Data was collected using a structured data extraction form. The Chi-square and the Student“s t-test were used to compare characteristics between adolescents and young adults. RESULTS: of 252 AYALHIV, 68% (172/252) were adolescents with a median age of 17 years (IQR 13-19); 32% were young adults with a median age of 22 years (IQR: 20-24). Most (56.7% (143/252)) AYALHIV were female. Almost 40% were orphans. Eighty-six percent of AYALHIV had HIV type I infection. The commonest mode of HIV acquisition among adolescents was vertical transmission (70.5%) and that among young adults was via unprotected sex (31.3%). 88% of AYALHIV were on non-nucleoside reverse transcriptase inhibitors-based regimen. The viral suppression rate among AYALHIV was 78%. CONCLUSION: the study shows there is a growing population of AYALHIV most of which are adolescents. About two-fifths were orphans. Policymakers and HIV programs should ensure AYALHIV-centred interventions are developed for this vulnerable population.


  • Open Access

    Evaluation of treatment outcomes among adult patients diagnosed with tuberculosis in Ghana: A 10 year retrospective review

    byĀ Peter Puplampu, Isaac Kyeremateng, Olive Asafu-Adjaye, Anita Ago Asare, Kofi Agyabeng, Roderick Sarkodee, Oladele Oluwakemi, Vincent Ganu